Evaluation of the Effects of Atomoxetine on Human Organs: A Systematic Review

Main Article Content

Hossein Karballaei Mirzahosseini
Mohammad Ghenaat Pisheh Sanani
Yasaman Mousavi Azad


Atomoxetine is a norepinephrine reuptake inhibitor. It is used to treat ADHD syndrome through increasing norepinephrine concentration in the synapses and consequently overstimulation of adrenergic receptors. Though, in recent years several reports have been published on the adverse effects and complications of atomoxetine overuse. As a result, this study is conducted to assess the effects of atomoxetine on different human organs. This is a review article in which 54 relevant papers have been evaluated- these studies were found through searching in valid electronic and library databases such as PubMed, Scopus, Google Scholar, Medline, and Embase to assess treatment protocols, effectiveness, and adverse effects of atomoxetine. Clinical and experimental studies have proved the side effects and complications of high-dose atomoxetine on weight loss, urinary system complications, cardiovascular issues, liver disorders, behavioural and nervous system problems. Results of the evaluated studies suggest that many patients arbitrarily use high-dose atomoxetine for long-term which may lead to irreversible problems and complications. Consequently, avoiding high-dose atomoxetine is suggested especially in pregnant women and patients with liver disorders.

Atomoxetine, side effect, ADHD, human organs, review

Article Details

How to Cite
Mirzahosseini, H. K., Sanani, M. G. P., & Azad, Y. (2019). Evaluation of the Effects of Atomoxetine on Human Organs: A Systematic Review. Journal of Pharmaceutical Research International, 31(3), 1-8. https://doi.org/10.9734/jpri/2019/v31i330301
Systematic Review Article


Leonard MA, Milich R, Lorch EP. The role of pragmatic language use in mediating the relation between hyperactivity and inattention and social skills problems. J Speech Lang Hear Res. 2011;54(2):567-79.

Sadock BJ, Sadock VA. Attention deficit hyperactivity disorder. Synopsis of psychiatry. 7th. New York: Lippincott, Williams and Wilkins. 2008;1206-17.

McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong ICK. The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care. BMC Pediatrics. 2012;12(1):1.

Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine/Methylphenidate Comparative Study Group. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008;165(6):721-730.

Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067.

Friedman JI, Carpenter D, Lu J, et al. A pilot study of adjunctive atomoxetine treatment to second-generation anti-psychotics for cognitive impairment in schizophrenia. J Clin Psychopharmacol. 2008;28(1):59–63.

Hennissen L, Bakker MJ, Banaschewski T, Carucci S, Coghill D, Danckaerts M, et al. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: A systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. CNS Drugs. 2017;31(3):199-215.

Fuentes J, et al. Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2013; 33(6):766–74.

Go S, Saito N, Suzuki S, Hatsushika T, Kato K, Kasuga A, et al. Atomoxetine-induced hyperadrenergic postural tachycardia syndrome: A case report. Clin Auton Res. 2018;28(2):247-9.

Lambert E, Eikelis N, Esler M, et al. Altered sympathetic nervous reactivity and norepinephrine transporter expression in patients with postural tachycardia syndrome. Circ Arrhythm Electrophysiol. 2008;1(2):103–109.

Wender P, Reimherr F, Marchant B, Sanford M, Czajkowski L, Tomb D. A one year trial of methylphenidate in the treatment of ADHD. J. Atten. Disord. 2010;15:36–45.

Arnold L. Methylphenidate vs. Dextroamphetamine vs. Caffeine in Minimal Brain Dysfunction. Arch. Gen. Psychiatry. 1978;35:463–473.

Findling R, Short E, Manos M. Short-term cardiovascular effects of methylphenidate and adderall. J. Am. Acad. Child Adolesc. Psychiatry. 2001;40:525–529.

Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer TA. Randomized placebo-controlled trial of OROS methylphenidate in Adults with Attention-Deficit/Hyperactivity Disorder. Biol. Psychiatry. 2006;59:829–835.

Tannock R, Schachar R, Carr R, Logan G. Dose-response effects of methylphenidate on academic performance and overt behavior in hyperactive children. Am. Acad. Pediatr. 1989;84:648–657.

Rösler M, Fischer R, Ammer R, Ose C, Retz W. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur. Arch. Psychiatry Clin. Neurosci. 2009;259: 120–129.

Ginsberg Y, Lindefors N. Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: Randomised double-blind placebo-controlled trial with open-label extension. Br. J. Psychiatry. 2012;200:68–73.

Bouffard R, Hechtman L, Minde K, Iaboni-Kassab F. The Efficacy of 2 different dosages of methylphenidate in treating adults with Attention-Deficit Hyperactive Disorder. Can. J. Psychiatry. 2003;48:546–554.

Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/ hyperactivity disorder. Eur. Neuropsycho-pharmacol. 2013;23:1208–1218.

Silva R, Muniz R, Pestreich L, Brams M, Childress A, Lopez F. Efficacy of Two Long-Acting Methylphenidate Formulations in Arcieri R, Germinario E, Bonati M, Masi G, Zuddas A, Vella SChiarotti F, Panei P. Italian Attention-Deficit/Hyperactivity Disorder Regional Reference Centers. Cardiovascular Measures in Children and Adolescents with Attention-Deficit/ Hyperactivity Disorder Who Are New Users of Methylphenidate and Atomoxetine. J. Child Adolesc. Psychopharmacol. 2012;22: 423–431.

Guertin J, LeLorier J, Durand M, Gow R, Holbrook A, Levine M. Impact of a restrictive drug access program on the risk of cardiovascular encounters in children exposed to ADHD Medications. J. Popul. Ther. Clin. Pharmacol. 2014;21:e357–e369.

Cortese S, Panei P, Arcieri R, Germinario E, Capuano A, Margari LChiarotti F, Curatolo P. Safety of methylphenidate and atomoxetine in children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry. CNS Drugs. 2015;29:865–877.

Ruggiero S, Rafaniello C, Bravaccio C, Grimaldi G, Granato R, Pascotto A, Sportiello L, Parretta E, Rinaldi B, Panei P, et al. Safety of Attention-Deficit/ Hyperactivity Disorder Medications in Children: An intensive pharmaco surveillance monitoring study. J. Child Adolesc. Psychopharmacol. 2012;22:415–422.

Shang C, Pan Y, Lin H, Huang L, Gau S. An Open-label, randomized trial of methylphenidate and atomoxetine treatment in children with Attention-Deficit/ Hyperactivity Disorder. J. Child Adolesc. Psychopharmacol. 2015;25:566–573.

Virani SS, Khan AN, Mendosa CE, et al. Takotsubo cardiomyopathy or broken-heart syndrome. Tex Heart Inst J. 2007;34:76–79.

Madias J. Atomoxetine resulting in takotsubo syndrome: Is the locally-released norepinephrine from the autonomic sympathetic cardiac nerves or the blood-borne catecholamines the cause? Eur J Pediatr. 2014;173:1119–1120.

Naguy A, Al-Mutairi H, Al-Tajali A. Atomoxetine-related Takotsubo Cardiomyopathy. J Psychiatr Pract. 2016;22(3):232-3.

Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J. Am. Acad. Child Adolesc. Psychiatry. 2007;46:242–251.

Kelly RP, Yeo KP, Teng CH, Smith BP, Lowe S, Soon D, Read HA, Wise SD. Hemodynamic effects of acute administration of atomoxetine and methylphenidate. J. Clin. Pharmacol. 2005; 45:851–855.

Kratochvil CJ, Newcorn JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005; 44(9):915–924.

Harfterkamp M, Van de Loo-Neus G, Minderaa RB, et al. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(7):733–741.

Wilens TE, Adler LA, Weiss MD, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend. 2008; 96(1–2):145–154.

Sumner CR, Schuh KJ, Sutton VK, Lipetz R, Kelsey DK. Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis. J Child Adolesc Psychopharmacol. 2006;16(6):699-711.

Glazener CM, Evans JH. Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev. 2002;3.

Michelson D, Faries DE, Wernicke J, Kelsey DK, Kendrick KL, Sallee FR, Spencer T, Atomoxetine ADHD Study Group: Atomoxetine in the treatment of children and adolescents with attentiondeficit/ hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108:e83.

Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D: Once-daily atomoxetine treatment for children and adolescents with attentiondeficit/ hyperactivity disorder: A randomized, placebo-controlled study. Am J Psychiatry. 1896–1901;2002;159.

Spencer TJ, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attentiondeficit/ hyperactivity disorder. J Clin Psychiatry. 2002;63:1140–1147.

Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D. Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53:112–120.

Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ. Once-daily atomoxetine treatment for children with attentiondeficit/ hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004;114:e1–e8.

Weiss M, Tannock R, Kratochvil C, Dunn D, Velez- Borras J, Thomason C, Tamura R, Kelsey D, Stevens L, Allen AJ. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44:647–655.

Fredriksen M, Halmøy A, Faraone SV, Haavik J. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: A review of controlled and naturalistic studies. Eur Neuro psychopharmacol. 2013;23(6):508-27.

Hammerness P, McCarthy K, Mancuso E, Gendron C, Geller D. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: A review. Neuropsychiatr Dis Treat. 2009; 5:215-26.

Racicka E, Hanc T, Giertuga K, et al. Prevalence of overweight and obesity in children and adolescents with ADHD: The significance of comorbidities and pharmacotherapy. J Atten Disord. 2018;22: 1095–1108. DOI:10.1177/1087054715578272.

Schwartz BS, Bailey-Davis L, Bandeen-Roche K, et al. Attention deficit disorder, stimulant use, and childhood body mass index trajectory. Pediatrics. 2014;133 (4):668–676.

Rimmer JH, Yamaki K, Davis BM, et al. Peer reviewed: Obesity and overweight prevalence among adolescents with disabilities. Prev Chronic Dis. 2011;8(2):A41.

Deshmukh AB, Deshmukh V, Shah M, Karira A, Karia S, Shah N, Sonavane S, Sousa A. Appetite and weight loss in children on atomoxetine therapy: an exploratory clinical study. International Journal of Contemporary Pediatrics. 2016;3(3):1041-1044.

Kobayashi H, Fujii K, Kobayashi M , Saito N, Okunushi K, Ebata R, Shiohama T, Sawada D, Shimojo N . Facial nerve palsy associated with atomoxetine-induced hypertension. Brain & Development; 2018. Available:https://doi.org/10.1016/j.braindev.2018.09

Potnis D, Wackernah RC. Drug-Induced Liver Injury in Children: Atomoxetine and Nonstimulants for ADHD. Am J Pharm Benefits. 2015;7(1):e15-e20.

Lachaine J, Beauchemin C, Sasané R, Hodgkins PS. Treatment patterns, adherence, and persistence in ADHD: A Canadian perspective. Postgrad Med. 2012;124(3):139-148.

Bushe CJ, Savill NC. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: Focus on clinical efficacy and safety. J. Psychopharmacol. 2014;28(3):204-211.

Bushe CJ, Savill NC. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: Focus on clinical efficacy and safety. J Psychopharmacol. 2014;28(3):204-211.

Children with Attention- Deficit/ Hyperactivity Disorder in a boratory Classroom Setting. J. Child dolesc. Psychopharmacol. 2005;15:637–654.